MGC Pharma: Pushing the envelope of phytocannabinoid-based research

Home > Media mentions > MGC Pharma: Pushing the envelope of phytocannabinoid-based research

Submitted by Linda McGlone

  • Media Title: Health Europa
  • Media Type: Online
  • Publish Date: 11 April 2019
  • Headline: MGC Pharma: Pushing the envelope of phytocannabinoid-based research
  • Abstract: MGC Pharma has a strong relationship with Epilepsy Action Australia, the country’s peak patient advocacy association. The relationship is varied, including collaboration on research, provision of information to patients, and more. In 2019, MGC Pharma co-funded the development of C4E (www.c4e.com.au), a platform that collates information about medicinal cannabis for the thousands of patients suffering from epilepsy in Australia.
  • Link: https://www.healtheuropa.eu/phytocannabinoid-based-research/91279

Share

Recent Posts

Message to the Australian Health Minister on epilepsy and Medicinal Cannabis >

Voices Behind Medicinal Cannabis – Special Presentation >

Please consider making a Tax Deductible Donation this Tax Time! >

PRESS RELEASE: New study reveals gaps in Australians’ understanding of epilepsy >

Categories

Archive

We acknowledge the Traditional Owners of the land where we work and live. We pay our respects to Elders past, present and emerging.

We celebrate the stories, culture and traditions of Aboriginal and Torres Strait Islander Peoples of all communities who also work and live on this land.

Important Message: This information is not intended as medical advice. Do not make changes to treatment or medications without first discussing with your treating clinician.